Clinical Trial

FemDx Medsystems Announces Successful First-in-Human Study

SANTA CLARA, Calif.--(BUSINESS WIRE)--FemDx Medsystems, a pioneering medical device company focused on advancing gynecological diagnostics, is proud to announce the…

8 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies…

8 months ago

Equiva and Belong.Life Partner to Equip Healthcare Providers with Validated Health AI Mentors for Better Patient Outcomes

Collaboration Projected To Generate Around $10 Million In Revenue Over The Next Three Years NEW YORK, April 28, 2025 /PRNewswire/ --…

8 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active…

8 months ago

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital…

8 months ago

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA®…

8 months ago

Cannabix Enters Sales Distribution Agreement with Alco Prevention Canada for BreathLogix Autonomous Alcohol Breathalyzer

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settingsVANCOUVER, British…

8 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK,…

8 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction

Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent PaymentsAntev is developing Teverelix, A…

8 months ago

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025…

8 months ago